- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03892837
Clinical Study on Autologous Platelet-rich Plasma (PRP) Treatment for Refractory Benign Airway Stenosis
March 26, 2019 updated by: ShiYue Li, Guangzhou Institute of Respiratory Disease
Platelet-rich plasma(PRP), is a concentrate of platelet-rich plasma protein derived from whole blood.
The main components of it are platelets, leukocytes and fibrin.
Autologous PRP treatment can avoid the immune rejection caused by exogenous growth factor and the spread of disease.
Evidence of the efficacy and safety of PRP has been proven in many studies.
Benign central airway stenosis is characterized by airway compromise involving the larynx, trachea, or bronchi and will lead to devastating consequences.
Unfortunately, the incidence of this disease is increasing steadily.
As most important treatment for benign airway stenosis, respiratory intervention has become one of the most common treatments to fight the disease.
However, the restenosis caused by tissue hyperplasia, wound repair and scar formation after treatment is still common, which remains the limitation of respiratory intervention.
Long-term efficacy of repeated interventional treatment is unsatisfying, too.
Several studies have discovered similar mechanism between stenosis of tracheal to hyperplastic scar of skin, both of which are relative with deep structure injury such as the intrinsic layer of airway mucosa.
PRP has shown significant efficacy for hyperplastic scar of skin.
Correspondingly, PRP will be applied as treatment of refractory benign airway stenosis to reduce restenosis by inhibit the formation of granulation.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaobo Chen, MD
- Phone Number: 86-020-83062885
- Email: xiaobo-win@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with aged between 18 to 75
- Subjects diagnosed with refractory benign airway stenosis and meet the following conditions: a. Received two or more (including two) interventional treatments such as laser, high-frequency electrosurgical unit, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement. b. Restenosis within 1 month after more than 2 times interventional treatments suffering from repeated granulation hyperplasia of wound
- Subjects tolerant to bronchoscope;
- Subjects signed informed consent
Exclusion Criteria:
- Subjects with airway disease:congenital benign central airway stenosis, recurrent polychondritis, etc;
- Subjects with the following pulmonary diseases: asthma, active pulmonary tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, etc;
- Subjects with malignant tumors or have a history of malignant tumors;
- Subjects with uncontrolled systemic infection;
- Subjects requiring anti-clotting drugs;
- Subjects with myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis, etc;
- Subjects with syphilis, HIV,HBV,HCV antibody positive;
- Subjects with Coagulation disorders such as hemophilia, giant platelet syndrome, thromboasthenia, etc;
- Subjects with severe renal damage, serum creatinine is more than 1.5 times the upper limit of the normal value;
- Subjects with liver disease or liver damage: ALT,AST, total bilirubin > 2 times the upper limit of the normal value;
- Subjects with a history of psychosis or suicide or epilepsy or other central nervous system diseases;
- Subjects with severe arrhythmias(e.g. ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or degree II above abnormal conduction;
- Subjects allergic to thrombin;
- Subjects accepted by any other clinical study within the first three months of the study;
- Subjects with poor compliance;
- Any other conditions might increase the risk of the patient or interfere with the clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control group
Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
|
Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
|
EXPERIMENTAL: PRP group
Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis.
Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
|
Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure rate for benign stenosis
Time Frame: within 6 months after administration
|
Proportion of patients who is no need for endotracheal intervention and with stable clinical symptoms after PRP treatment
|
within 6 months after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Times of unplanned treatment
Time Frame: within 6 months after administration
|
The number of times a patient needs to be reviewed and treated by bronchoscopy for cough, expectoration and dyspnea
|
within 6 months after administration
|
Clinical remission time
Time Frame: 6 months after administration
|
The interval time of the first intratracheal interventional therapy needed again after 6 times of PRP treatment
|
6 months after administration
|
Incidence of complications associated with PRP treatment
Time Frame: within 6 months after administration
|
Wound healing, sputum retention, etc. during follow-up
|
within 6 months after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shiyue Li, MD, Guangzhou Institute of Respiratory Disease
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
April 1, 2019
Primary Completion (ANTICIPATED)
September 1, 2020
Study Completion (ANTICIPATED)
April 1, 2021
Study Registration Dates
First Submitted
March 26, 2019
First Submitted That Met QC Criteria
March 26, 2019
First Posted (ACTUAL)
March 27, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 27, 2019
Last Update Submitted That Met QC Criteria
March 26, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-03-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Airway Stenosis
-
Guangzhou Institute of Respiratory DiseaseRecruitingRespiratory Tract Fistula | Benign Airway StenosisChina
-
Duke UniversityCompletedCentral Airway Stenosis | Disorder Related to Lung Transplantation | Airway Exudative Plaques | Airway Complications Post-Lung TransplantationUnited States
-
Deep BreezeCompletedCentral Airway StenosisUnited States, France, Germany, Japan
-
Futian People's HospitalScience and Technology Innovation Commission of Shenzhen MunicipalityUnknownCentral Airway Stenosis | Noninvasive Positive Pressure Ventilation; | Sedation; | Bronchoscopy; | Interventional;China
-
University Hospital, ToulouseRecruiting
-
University of Cape TownRed Cross War Memorial Children's HospitalUnknownPediatric Respiratory Diseases | Tracheal Stenosis | Airway DiseaseSouth Africa
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingEsophageal Atresia | Tracheoesophageal Fistula | Tracheal Stenosis | Laryngeal Cleft | Bronchial Stenosis | Esophageal Bronchus | Congenital High Airway Obstruction SyndromeUnited States
-
Radboud University Medical CenterUnknownBenign Esophageal StrictureNetherlands
-
Brigham and Women's HospitalNot yet recruiting
-
Radboud University Medical CenterELLA-CS , sroUnknownBenign Esophageal Stricture
Clinical Trials on Conventional treatment for benign airway stenosis
-
Massachusetts General HospitalUniversity of Colorado, DenverCompletedAortic Valve StenosisUnited States
-
Centre Hospitalier Universitaire de NiceInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Capital Medical UniversityUnknownHeadache | Intracranial Hypertension | Tinnitus | Visual Impairment | Stent Stenosis | Papilledema
-
liuxingjuNational Clinical Research Center for Neurological DiseasesUnknownAtherosclerotic Intracranial Arterial Stenosis With Intracranial AneurysmsChina
-
Helwan UniversityActive, not recruitingBenign Prostatic HyperplasiaEgypt
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingSudden Sensorineural Hearing LossChina
-
Istituto Ortopedico RizzoliCompletedLumbar Spinal StenosisItaly
-
Hospital Universitario La PazHospital Universitario Principe de AsturiasWithdrawnSleep Apnea | DyslipidaemiaSpain
-
Hospital Universitario Ramon y CajalRecruitingSleep Apnea, Obstructive | PolycythemiaSpain
-
Hospital Universitario La PazCompletedCPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea (DIANA)Diabetic Nephropathy | Sleep ApneaSpain